(Total Views: 335)
Posted On: 04/28/2021 3:33:26 PM
Post# of 36563
I feel like GNBT is all-in with the vaccine:
"If the Vaccine fails in its clinical trials, Generex will compensate the Joint Entity through one of two methods:
1. Generex will grant the Joint Entity sole and exclusive use of its technology and related intellectual property in Excellagen for a license fee of $10 million less the $5 million paid to Generex pursuant to the Covid Agreement and the remaining $5 million will be paid to Generex following NMPA approval; or
2. Generex will grant the Joint Entity with a sole and exclusive license for the whole Ii-Key platform which includes infectious diseases and cancer for a $50 million license fee less the $5 million license fee paid to Generex pursuant to the Covid Agreement.
"
If only the phase I is successful, it should increase the PPS enough to get significant money by diluting a bit.
"If the Vaccine fails in its clinical trials, Generex will compensate the Joint Entity through one of two methods:
1. Generex will grant the Joint Entity sole and exclusive use of its technology and related intellectual property in Excellagen for a license fee of $10 million less the $5 million paid to Generex pursuant to the Covid Agreement and the remaining $5 million will be paid to Generex following NMPA approval; or
2. Generex will grant the Joint Entity with a sole and exclusive license for the whole Ii-Key platform which includes infectious diseases and cancer for a $50 million license fee less the $5 million license fee paid to Generex pursuant to the Covid Agreement.
"
If only the phase I is successful, it should increase the PPS enough to get significant money by diluting a bit.
(2)
(0)
